Media headlines about Flex Pharma (NASDAQ:FLKS) have trended positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Flex Pharma earned a daily sentiment score of 0.28 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.7304541305506 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
NASDAQ:FLKS traded down $0.27 during trading hours on Monday, hitting $5.06. The company’s stock had a trading volume of 13,723 shares, compared to its average volume of 89,338. Flex Pharma has a 52-week low of $2.68 and a 52-week high of $8.98.
Flex Pharma (NASDAQ:FLKS) last posted its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.10. The firm had revenue of $0.28 million for the quarter, compared to analyst estimates of $0.36 million. Flex Pharma had a negative return on equity of 85.02% and a negative net margin of 2,698.59%. analysts predict that Flex Pharma will post -1.88 EPS for the current fiscal year.
A number of research firms have recently weighed in on FLKS. Cantor Fitzgerald reaffirmed a “hold” rating and set a $10.00 price objective on shares of Flex Pharma in a research report on Wednesday, January 17th. Zacks Investment Research lowered Flex Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Roth Capital reissued a “buy” rating and issued a $12.00 target price on shares of Flex Pharma in a report on Wednesday, January 3rd. ValuEngine lowered Flex Pharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, March 28th. Finally, Ladenburg Thalmann assumed coverage on Flex Pharma in a report on Thursday, January 25th. They issued a “buy” rating and a $12.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $8.55.
COPYRIGHT VIOLATION NOTICE: This report was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.thelincolnianonline.com/2018/04/16/flex-pharma-flks-earns-daily-media-impact-rating-of-0-28.html.
Flex Pharma Company Profile
Flex Pharma, Inc, a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company operates through two segments, Consumer Operations and Drug Development.
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.